Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (24,396,828)	$ (20,988,943)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	3,328,344	2,627,544
Depreciation and amortization	267,311	34,426
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(184,272)	(831,061)
Research and development tax incentive receivable	(103,307)	(1,168,553)
Prepaid assets and other assets	1,433,966	1,407,862
Accounts payable	148,657	269,433
Accrued compensation	(416,910)
Deferred revenue	312,710	(24,315)
Operating lease obligation	(29,869)
Net cash used in operating activities	(19,640,198)	(18,673,607)
Cash flows from investing activities:
Purchases of property and equipment	(1,410,159)	(741,853)
Net cash used in investing activities	(1,410,159)	(741,853)
Cash flows from financing activities:
Net proceeds from issuance of common stock	404,555	28,015,019
Proceeds from issuance of common stock for stock option exercises	10,185	689,753
Proceeds from issuance of common stock for warrant exercises		180,212
Net cash provided by financing activities	414,740	28,884,984
Effect of exchange rate changes on cash and cash equivalents	(11,965)	(54,586)
Net change in cash and cash equivalents	(20,647,582)	9,414,938
Cash and cash equivalents at beginning of period	33,794,672	35,300,805
Cash and cash equivalents at end of period	13,147,090	44,715,743
Supplemental disclosure of non-cash investing and financing activities:
Receivable for option exercise	100,637
Cashless exercise of warrants		416
ROU asset obtained under for new operating lease	$ 238,021